Table 2.

Endometrial cancer risk groups (Oaknin et al., 2022 [5]). The table can be used in stage III-IVA with complete resection without residual disease and does not apply to stage III-IVA with residual disease or for stage IV. dMMR, deficient mismatch repair; EC, endometrial cancer; G1-G3, grade 1-3; IHC, immunohistochemistry; LVSI, lymphovascular space invasion; MSI-H, microsatellite instability high/hypermutated; NSMP, no specific molecular profile; p53-abn, p53-abnormal; POLEmut, polymerase ε-ultramutated.

Risk Group	Description
Low risk	Stage IA (G1-G2) with endometrioid type (dMMR or MSI-H and NSMP) and no or focal LVSI Stage I–III POLEmut EC
Intermediate risk	Stage IA G3 with endometrioid type (dMMR and NSMP) and no or focal LVSI Stage IA non-endometrioid type (serous, clear-cell, undifferentiated carcinoma, carcinosarcoma, mixed) and/or p53-abn cancers without myometrial invasion and no or focal LVSI Stage IB (G1-G2) with endometrioid type (dMMR and NSMP) and no or focal LVSI Stage II G1 endometrioid type (dMMR and NSMP) and no or focal LVSI
High-intermediate risk	Stage I endometrioid type (dMMR and NSMP) any grade and any depth of invasion with substantial LVSI Stage IB G3 with endometrioid type (dMMR and NSMP) regardless of LVSI Stage II G1 endometrioid type (dMMR and NSMP) with substantial LVSI Stage II G2-G3 endometrioid type (dMMR and NSMP)
High risk	All stages and all histologies with p53-abn and myometrial invasion All stages with serous or undifferentiated carcinoma including carcinosarcoma with myometrial invasion All stage III and IVA with no residual tumor, regardless of histology and regardless of molecular subtype